Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 61

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Suprefort® Diabetes mellitus type II occurred in patients without any clinical manifestations and was diagnosed based on an increase in glucose level in the peripheral blood, taking into account an unbalanced diet. The control group consisted of 17 patients prescribed medication using conventional treatment. 22 patients included in the primary group, in addition to traditional therapy, including antihyperglycemic agents, received 1 capsule of SUPREFORT® 2 times a day before meals for 15 days. RESEARCH METHODS The patients’ complaints were assessed in dynamics, a general clinical examination of blood and urine, and a biochemical study of blood on the REFLOTRON apparatus (Boehringer Mannheim, Germany) were carried out. The duodenal contents were examined. A glucose tolerance test was performed. RESEARCH RESULTS It was found that the use of SUPREFORT® in patients with chronic pancreatitis promoted an increase in appetite and a decrease in the frequency of dyspeptic disorders. Influence of SUPREFORT® on the activity of digestive enzymes in Table 2 patients with chronic pancreatitis. Indicator Before Treatment After Treatment with Conventional After Treatment with Means Suprefort® Trypsin, (mmol/l) 2,14±0,09 2,72±0,12 2,9±0,1 α-amylase, kg / (h•l) 5,2±0,4 5,7±0,3 6,1±0,4 In a laboratory study of the duodenal contents, an initial decrease in the activity of pancreatic enzymes was noted (Table 2). As a result of the use of SUPREFORT®, there was a tendency to an increase in the activity of pancreatic enzymes, which correlated with an improvement in clinical symptoms. In patients with type II diabetes mellitus, SUPREFORT® was used under the control of a glucose tolerance test. After the sugar load, it was found that the patients had a characteristic glycemic curve. In addition to the conventional treatment, patients of the primary group were prescribed SUPREFORT® 1 capsule 2 times a day before meals for 10 days. It was shown that after the use of SUPREFORT®, when the test was performed in the second hour of the study, a gradual decrease in blood glucose levels was observed. Normalization of blood glucose levels was achieved in all patients 5-10 days after starting the drug. None of the patients received an increase in the dosage of antihyperglycemic drugs, 12 patients (54.5%) had a reduced dose of conventional medications, and in 7 patients (31.8%), the blood glucose level did not exceed normal values without the use of antidiabetic drugs. The indicators remained at the initial level in 3 patients (13.6%). It should be noted that the indicator of glucose in the blood of patients of the primary group stabilized during the next 2-3 months after the end of the course of treatment (Table 3). Influence of SUPREFORT® on blood glucose after carbohydrate load in patients Table 3 with type II diabetes mellitus. Blood glucose Control Group Primary Group (mmol/l) Before Treatment After Treatment Before Treatment After Treatment with with Conventional Suprefort® Methods On an empty stomach 8,2±0,9 6,6±0,4* 7,9±1,1 5,8±0,3* 2 hours after glucose intake 12,7±0,4 9,4±0,5 11,6±0,3 7,0±0,8* ** * P <0.05 - significant compared with the indicator before treatment; ** P <0.05 - significant compared with the indicator in patients of the control group.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.